TyG: A Calculated Proxy for Insulin Sensitivity
The Triglyceride–Glucose Index (TyG Index) is a calculated number derived from two routine fasting blood measurements: triglycerides and glucose. Triglycerides are the body's transport form of fat, carried in the bloodstream within lipoprotein particles (mainly VLDL from the liver). Glucose is the primary circulating sugar used by cells for energy. The TyG Index does not come from a single organ or molecule; it synthesizes these two metabolic signals into one composite indicator.
What it reflects is the body's response to insulin—the hormone that tells tissues to take up glucose and that restrains liver release of triglyceride-rich particles. When insulin signaling works well, fasting glucose stays controlled and triglyceride output from the liver remains low. When tissues become resistant to insulin (insulin resistance), both measures tend to drift upward together. The TyG Index therefore serves as an accessible proxy for whole-body insulin sensitivity, integrating muscle and liver metabolism, and linking sugar handling with fat traffic (glucose homeostasis and lipid metabolism).
Why Two Fasting Numbers Catch What A1c Misses
The TyG Index is a calculated score from fasting triglycerides and fasting glucose that captures how well your body handles fuel. It is a practical surrogate for insulin resistance, linking the liver (triglyceride production), muscle and fat (glucose uptake), and the pancreas (insulin output). Because it reflects two core energy pathways, it tracks risk across systems—metabolic syndrome, fatty liver, and cardiovascular disease.
It combines fasting triglycerides and fasting glucose into a single score that tracks how well your body handles both fuels together. Because insulin coordinates energy use across liver, muscle, fat tissue, and the vascular endothelium, TyG links to metabolic efficiency, cardiovascular risk, liver fat, reproductive function, and brain energy metabolism.
Reading a TyG Score Across the Range
There is no universal cutoff used by all labs, but in general, lower values indicate better insulin sensitivity and metabolic flexibility, and "within reference ranges" tends to sit toward the lower end of typical population ranges. When the index is low, it usually means triglycerides are modest and fasting glucose is well controlled: the liver isn't oversupplying fat, muscles respond to insulin, and the pancreas works efficiently. Very low values are uncommon; when driven by recurrent low glucose or poor nutrient absorption, people may notice shakiness, lightheadedness, or unintended weight loss.
When the index runs high, it signals insulin resistance: the liver exports more triglyceride-rich particles, muscle and fat resist insulin's signal, and the pancreas compensates with higher insulin. People may experience waist-centered weight gain, fatigue after meals, elevated blood pressure, skin tags or darkened skin folds (acanthosis). Women may see cycle irregularity consistent with insulin resistance phenotypes; adolescents can show early metabolic strain; during pregnancy, higher values have been linked with greater risk of gestational diabetes.
Low values usually reflect effective insulin action with good glucose uptake and low hepatic VLDL output—metabolic flexibility with stable energy use. System-level effects include favorable lipid particle profile and lower inflammatory tone. Very low values can also occur with undernutrition, chronic illness, or unusually low triglycerides or glucose.
High values usually reflect insulin resistance, with impaired muscle glucose uptake and increased liver triglyceride production. This pattern clusters with central adiposity, elevated blood pressure, fatty liver, atherogenic dyslipidemia, and higher type 2 diabetes and cardiovascular event risk. It is often higher in men than women, rises with age, and in pregnancy tends to increase across trimesters; higher values are linked to gestational diabetes and, in women, polycystic ovary syndrome.
What Can Shift a TyG Reading
Interpret on a true fasting sample. Recent illness, stress, alcohol, and high-fat or high-carb meals can transiently raise the index. Common medications (glucocorticoids, some antipsychotics, thiazides, beta‑blockers, estrogens/androgens, retinoids) and thyroid status influence results. Different labs may use slightly different calculation conventions.
What to Pair With TyG for a Full Cardiometabolic Picture
Persistently higher values align with hepatic fat accumulation, atherogenic dyslipidemia, rising glucose over time, and events such as type 2 diabetes and cardiovascular disease. It complements other markers (A1c, HDL, ALT, waist circumference), helping map long-term cardiometabolic health.
What a TyG Index Tells You Over Time
TyG integrates lipid and glucose physiology into one risk signal. In population studies, risk for metabolic syndrome and atherosclerotic disease tends to be lowest toward the lower end of the reference span rather than the high end. Tracked over time, falling TyG mirrors improving insulin sensitivity and a lower cardiometabolic risk profile.
FAQs
TyG Index testing uses fasting triglyceride and fasting glucose values to calculate a single metric that reflects insulin resistance and overall metabolic health.
Testing the TyG Index provides early insight into insulin resistance and adds context to cardiometabolic and liver risk beyond standard lipids or glucose alone.
When making lifestyle changes, recheck every 8–12 weeks to track response. For general monitoring, quarterly to twice yearly is common.
Dietary pattern, physical activity, body composition, sleep, stress, illness, and medications can shift fasting triglycerides and glucose, influencing the TyG Index.
Yes. Because it is calculated from fasting labs, fast for 8–12 hours (water is fine) and avoid heavy exercise and alcohol the day before the blood draw.
Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.
We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.
References
- Feingold, K. R. (2024). Introduction to lipids and lipoproteins. In Endotext. MDText.com, Inc. https://www.ncbi.nlm.nih.gov/books/NBK305896/
- Liu, X., Tan, Z., Huang, Y., Zhao, H., Liu, M., Yu, P., Ma, J., Zhao, Y., Zhu, W., & Wang, J. (2022). Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: A systematic review and meta-analysis. Cardiovascular Diabetology, 21(1), 124. https://doi.org/10.1186/s12933-022-01546-0
- Nordestgaard, B. G. (2016). Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: New insights from epidemiology, genetics, and biology. Circulation Research, 118(4), 547-563. https://doi.org/10.1161/CIRCRESAHA.115.306249
- McLaughlin, T., Abbasi, F., Cheal, K., Chu, J., Lamendola, C., & Reaven, G. (2003). Use of metabolic markers to identify overweight individuals who are insulin resistant. Annals of Internal Medicine, 139(10), 802-809. https://doi.org/10.7326/0003-4819-139-10-200311180-00007
- Nordestgaard, B. G., Langsted, A., Mora, S., Kolovou, G., Baum, H., Bruckert, E., Watts, G. F., Sypniewska, G., Wiklund, O., Borén, J., Chapman, M. J., Cobbaert, C., Descamps, O. S., von Eckardstein, A., Kamstrup, P. R., Pulkki, K., Kronenberg, F., Remaley, A. T., Rifai, N., ... Langlois, M. (2016). Fasting is not routinely required for determination of a lipid profile: Clinical and laboratory implications including flagging at desirable concentration cut-points—A joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal, 37(25), 1944-1958. https://doi.org/10.1093/eurheartj/ehw152






































.avif)
